Literature DB >> 23124932

Validation of a coding algorithm to identify patients with hepatocellular carcinoma in an administrative database.

David S Goldberg1, James D Lewis, Scott D Halpern, Mark G Weiner, Vincent Lo Re.   

Abstract

PURPOSE: International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM)-based algorithms to identify patients with hepatocellular carcinoma (HCC) have not been developed outside of the Veterans Affairs healthcare setting. The development and validation of such algorithms are necessary for the conduct of population-based studies evaluating the epidemiology and comparative effectiveness and safety of therapies for HCC.
METHODS: We queried electronic medical records at two tertiary care hospitals to identify patients with two ICD-9-CM diagnosis codes for a chronic liver disease and/or cirrhosis plus two ICD-9-CM codes for HCC. We determined the positive predictive value (PPV) of this algorithm by comparing it to diagnoses of HCC confirmed by expert medical record review.
RESULTS: Among 101 patients meeting the algorithm, 88 (PPV: 87.1%; 95% CI: 79.0-93.0%) had confirmed HCC. The algorithm's sensitivity was 91.7% among patients with confirmed HCC, and its specificity was 98.7% among chronic liver disease patients without HCC. Excluding patients who received systemic chemotherapy in the 12 months prior to or 6 months after the initial ICD-9-CM code in the algorithm, the PPV increased to 91.6% (87/95; 95% CI: 84.1-96.3%).
CONCLUSIONS: The presence of at least two ICD-9-CM codes for a chronic liver disease and/or cirrhosis plus two ICD-9-CM codes for HCC has a high PPV for identifying HCC cases. This simple, claims-based algorithm can be used in future epidemiologic studies to examine risk factors for HCC and evaluate outcomes and adverse events of medical therapies prescribed for HCC patients.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 23124932      PMCID: PMC3540172          DOI: 10.1002/pds.3367

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  16 in total

1.  Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection.

Authors:  Fasiha Kanwal; Tuyen Hoang; Jennifer R Kramer; Steven M Asch; Matthew Bidwell Goetz; Angelique Zeringue; Peter Richardson; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2010-12-22       Impact factor: 22.682

2.  Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.

Authors:  Jessica A Davila; Robert O Morgan; Peter A Richardson; Xianglin L Du; Katherine A McGlynn; Hashem B El-Serag
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

3.  Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States.

Authors:  Jessica A Davila; Zhigang Duan; Katherine A McGlynn; Hashem B El-Serag
Journal:  J Clin Gastroenterol       Date:  2012-01       Impact factor: 3.062

4.  Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA.

Authors:  Hashem B El-Serag; Jennifer R Kramer; G John Chen; Zhigang Duan; Peter A Richardson; Jessica A Davila
Journal:  Gut       Date:  2011-01-21       Impact factor: 23.059

5.  Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.

Authors:  Tania M Welzel; Barry I Graubard; Stefan Zeuzem; Hashem B El-Serag; Jessica A Davila; Katherine A McGlynn
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

6.  Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.

Authors:  Jessica A Davila; Louise Henderson; Jennifer R Kramer; Fasiha Kanwal; Peter A Richardson; Zhigang Duan; Hashem B El-Serag
Journal:  Ann Intern Med       Date:  2011-01-18       Impact factor: 25.391

7.  Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database.

Authors:  D Goldberg; Jd Lewis; Sd Halpern; Mark Weiner; Vincent Lo Re
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-06-04       Impact factor: 2.890

Review 8.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

9.  Utilization of screening for hepatocellular carcinoma in the United States.

Authors:  Jessica A Davila; Allan Weston; Walter Smalley; Hashem B El-Serag
Journal:  J Clin Gastroenterol       Date:  2007-09       Impact factor: 3.062

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  27 in total

1.  Combining billing codes, clinical notes, and medications from electronic health records provides superior phenotyping performance.

Authors:  Wei-Qi Wei; Pedro L Teixeira; Huan Mo; Robert M Cronin; Jeremy L Warner; Joshua C Denny
Journal:  J Am Med Inform Assoc       Date:  2015-09-02       Impact factor: 4.497

2.  Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.

Authors:  David Goldberg; Ivo C Ditah; Kia Saeian; Mona Lalehzari; Andrew Aronsohn; Emmanuel C Gorospe; Michael Charlton
Journal:  Gastroenterology       Date:  2017-01-11       Impact factor: 22.682

3.  Ascertainment of acute liver injury in two European primary care databases.

Authors:  A Ruigómez; R Brauer; L A García Rodríguez; C Huerta; G Requena; M Gil; Francisco de Abajo; G Downey; A Bate; M Feudjo Tepie; M de Groot; R Schlienger; R Reynolds; O Klungel
Journal:  Eur J Clin Pharmacol       Date:  2014-07-29       Impact factor: 2.953

4.  Liver-related mortality is similar among men and women with cirrhosis.

Authors:  Nikhilesh R Mazumder; Stela Celaj; Kofi Atiemo; Amna Daud; Kathryn L Jackson; Abel Kho; Josh Levitsky; Daniela P Ladner
Journal:  J Hepatol       Date:  2020-04-25       Impact factor: 25.083

5.  An algorithm to identify the development of lymphedema after breast cancer treatment.

Authors:  Tina W F Yen; Purushuttom W Laud; Rodney A Sparapani; Jianing Li; Ann B Nattinger
Journal:  J Cancer Surviv       Date:  2014-09-04       Impact factor: 4.442

6.  Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study.

Authors:  Kim A Reiss; Shun Yu; Ronac Mamtani; Rajni Mehta; Kathryn D'Addeo; E Paul Wileyto; Tamar H Taddei; David E Kaplan
Journal:  J Clin Oncol       Date:  2017-09-05       Impact factor: 44.544

7.  Increased Distance to a Liver Transplant Center Is Associated With Higher Mortality for Patients With Chronic Liver Failure.

Authors:  David S Goldberg; Craig Newcomb; Richard Gilroy; Gurvaneet Sahota; Anna E Wallace; James D Lewis; Scott D Halpern
Journal:  Clin Gastroenterol Hepatol       Date:  2017-02-27       Impact factor: 11.382

8.  Validation of a coding algorithm to identify bladder cancer and distinguish stage in an electronic medical records database.

Authors:  Ronac Mamtani; Kevin Haynes; Ben Boursi; Frank I Scott; David S Goldberg; Stephen M Keefe; David J Vaughn; S Bruce Malkowicz; James D Lewis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-11-11       Impact factor: 4.254

9.  Mortality Risk Factors Among Patients With Cirrhosis and a Low Model for End-Stage Liver Disease Sodium Score (≤15): An Analysis of Liver Transplant Allocation Policy Using Aggregated Electronic Health Record Data.

Authors:  K Atiemo; A Skaro; H Maddur; L Zhao; S Montag; L VanWagner; S Goel; A Kho; B Ho; R Kang; J L Holl; M M Abecassis; J Levitsky; D P Ladner
Journal:  Am J Transplant       Date:  2017-04-04       Impact factor: 8.086

10.  Use of Population-based Data to Demonstrate How Waitlist-based Metrics Overestimate Geographic Disparities in Access to Liver Transplant Care.

Authors:  D S Goldberg; B French; G Sahota; A E Wallace; J D Lewis; S D Halpern
Journal:  Am J Transplant       Date:  2016-05-17       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.